Skip to main content

Table 2 Infectious complications, which led to a medical consultation in the 12 months after aHSCT

From: Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation

Infection (causative agent if available) Frequency Occurrence after aHSCT, month Treatment Treatment duration, weeks
CMV reactivation 3/17 (17.6%); 3/6 of CMV IgG positive (50.0%) 1 Valganciclovir 8 (prophylactic)
1 Valganciclovir 8 (prophylactic)
1 Ganciclovir 5
EBV reactivation 1/17 (5.9%) 2 Rituximab 2 × 1 g 2
Mycosis 3/17 (17.6%)    
 Nodular pneumonia 1 Voriconazole 5
 Oral candidiasis 9 Nystatin 12 (prophylactic)
 Esophageal candidiasis 6 Fluconazole 2
Upper respiratory tract infection 3/17 (17.6%) 9 Non na
1 Azithromycin 24 (prophylactic)
10 Amoxicillin/clavulanic acid 1
Atypical pneumonia 1/17 (5.6%) 3 Piperacillin/tazobactam + linezolid 2
Pyelonephritis (Escherichia coli) 1/17 (5.9%) 11 Ciprofloxacin 1
Superinfected pancreatic pseudocyst (Streptococcus anginosus + Enterococcus faecalis and cloacae + Klebsiella pneumoniae) 1/17 (5.9%) 3 Ceftriaxone + metronidazole, meropenem, ciprofloxacin; drainage, piperacillin/tazobactam, linezolid 14
Lethal pneumonia with lactate acidosis 1/17 (5.9%) 9 Piperacillin/tazobactam 1
  1. CMV cytomegalovirus, EBV Epstein-Barr virus, na not applicable